Multiple sclerosis in south Cambridgeshire: incidence and prevalence based on a district register

N Robertson, J Deans, M Fraser, D A S Compston

Abstract

Study objective – To establish an updated prevalence and incidence figure for multiple sclerosis on 1 July 1993, to determine the fate of the 374 patients prevalent in 1990, and to establish the origin of incident patients.

Design – Case ascertainment was from several sources including departmental records, local branches of the Multiple Sclerosis Society, general practitioners, nursing homes, and residential facilities for the disabled. Data collection was by personal interview using a standardised questionnaire and by retrospective analysis of departmental case notes. A prospective incidence register of newly diagnosed patents was maintained from 1990.

Setting – The Cambridge Health District of East Anglia covering 340,910 hectares in area and a population of 290,700.

Patients – Altogether 441 patients prevalent on 1 July 1993 were identified, of whom 328 were contacted so that clinical data could be collected. Seventy patients (16%) either declined to take part or access was denied by their general practitioner; 8 (2%) had died; and 35 (8%) were too ill or failed to respond to several requests for contact.

Main results – A comprehensive re-evaluation of the south Cambridgeshire multiple sclerosis register revealed a prevalence of 441/290,700 population (152/10^5) for all disease classifications on 1 July 1993. This represented an increase of 18% from 1990 and was a result of 138 additions and 71 deletions from the original list of 374 patients. The sex ratio of prevalent patients was 2.6 F:M, the mean age at disease onset was 31.7 years, and the mean age was 49 years. Mortality for 1990–93 was 3.3/10^5/year and prospective maintenance of an incidence register recorded 96 new diagnoses for all classifications of multiple sclerosis over the five year period 1990–94 (6.6/10^5/year).

Conclusions – The increase in prevalence mainly resulted from improved case ascertainment identifying a further 58 patients who had been prevalent in 1990. Comparisons with other serial studies within the United Kingdom show similarities in proportional increase with successive studies indicating that serial survey may in part account for the observed latitudinal gradient within the United Kingdom. However, the observed prevalence (152/10^5) in this second survey still falls short of the figure estimated from incidence and mortality data (186/10^5).

The relatively few epidemiological studies of multiple sclerosis which have maintained large population based registers and provide the opportunity for serial measurements of prevalence have been especially influential in generating hypotheses for causation of the disease. In particular, studies in north east Scotland recorded the highest known prevalence and spawned the observation of a latitudinal gradient for the disease. The existence of this gradient seems indisputable; however, despite extensive investigation no environmental agent which explains this phenomenon has been identified. With increasing evidence of a genetic contribution to disease aetiology, it is of considerable importance to establish whether this gradient exists between or within genetically homogenous populations, or alternatively is an artefact of enhanced ascertainment resulting from serial estimations of prevalence in defined areas.

The Cambridgeshire register of patients with multiple sclerosis was established in 1989 and presented prevalence data from the Cambridge Health District on July 1, 1990, demonstrating a combined disease prevalence of 130/10^5 for suspected and probable/definite multiple sclerosis in this previously unsurveyed population. The register has since been maintained and incidence data have been collected prospectively since January 1990. A comprehensive re-evaluation of the population was undertaken on July 1, 1993 in order to identify patients missed in the initial study, to establish a new prevalence rate, and to report five year incidence and mortality data for the period 1990–94. These statistics have allowed us to assess the extent to which epidemiological surveys underestimate the prevalence rate expected from incidence and mortality data.

STUDY AREA

Cambridgeshire is a land locked county, lying in a predominantly rural region within a recognised area of high disease prevalence between latitudes 50 and 52 degrees north of the equator, and covering an area of 340,910 hectares.
Multiple sclerosis in south Cambridgeshire

hectares. Its predominant geographical feature is of flat terrain, with extensive fenlands to the north and east of the county. It is separated into six county districts and is served by four health authorities, the largest of which is the Cambridgeshire health district, which provides care for the southern half of the county. Within its boundaries lie two large population centres – the university city of Cambridge and the city of Ely. Neurological services are provided by one regional centre based at Addenbrooke’s Hospital in Cambridge, and outpatient neurological services are also maintained by consultant staff from Cambridge working at four district general hospitals surrounding the study area. All inpatient investigation is performed at a single regional neurology unit in Cambridge and the department holds records for all patients seen since 1965, irrespective of domicile. The area is served by 350 general practitioners from 121 main surgeries and 30 branch surgeries, although some patients are registered with general practitioners outside the county boundaries. Population figures for the study area are published by the Cambridgeshire County Council Population Research Group, and report a 1991 mid-year estimate of 290,700.5

Methods

A preliminary register was established based on the patients originally identified in the 1990 survey and this has been maintained ever since. In addition, all 32,301 sets of departmental notes were re-examined in order to identify any individuals omitted from the first 1990 list. This preliminary register was entered into the family health services authority computer to identify those patients who were alive, resident in the study area, and currently registered with a general practitioner.

Three additional sources were used to identify patients with suspected or confirmed multiple sclerosis. The aims of the study were explained to all general practitioners within the Cambridge, Huntingdon, and Peterborough health districts and adjoining areas, and a record of patients believed to be registered with their practice on July 1 1990 was provided. General practitioners were asked for any amendments to identification details and permission to contact incident patients with suspected or confirmed multiple sclerosis who had not appeared on the original register. Reminders were sent at four monthly intervals to practitioners who did not respond. Secondly, all local branch secretaries of the Multiple Sclerosis Society of Great Britain and Northern Ireland were asked to provide membership lists. Thirdly, all nursing homes and facilities for the disabled were contacted to identify additional patients.

The methodology of case ascertainment closely followed the original study,4 but on this occasion no attempt was made to identify patients from the hospital inpatient database since no unique identifications had occurred from this source in 1990 and all neurological outpatient notes and inpatient discharge summaries had been scrutinised prospectively from that time.

Attempts were made to contact all patients on the provisional register in order to collect clinical data and confirm residence within the study area. Where this was not possible, hospital and/or primary case notes were reviewed. Clinical classifications used the criteria of Poser et al6 and Allison and Millar7 so that comparisons could be made with earlier studies. For the Poser criteria, as in the original study, clinically definite multiple sclerosis (CDMS), laboratory supported definite multiple sclerosis (LSDMS), clinically probable multiple sclerosis (CPMS), and laboratory supported probable multiple sclerosis (LSPMS) were collectively categorised as multiple sclerosis (MS); these were distinguished from cases with suspected multiple sclerosis and those with other neurological diseases. Age and sex specific prevalence was calculated as well as standardised prevalence rates, based on the 1961 population census of Northern Ireland.4 Results are compared with other second surveys, particularly those performed in the north east of Scotland,8–10 Northern Ireland,11–12 and south east Wales.13

The status of all 374 patients prevalent in 1990 was re-evaluated. Most were still prevalent, but some had died or moved out of the study area. In a few the diagnosis of multiple sclerosis had been refuted and a number of patients with suspected multiple sclerosis had changed diagnostic category. In addition, all new diagnoses of multiple sclerosis made by Cambridge based neurologists were used to derive incidence figures over a five year period from January 1990 to December 1994, after categorising patients according to whether they were newly diagnosed, had moved into the study area, or were prevalent in July 1990 but not ascertained.

Results

The provisional register contained 662 patients from all sources. Every general practice responded to the request to participate in the study; but two elected not to provide lists of patients because of concerns regarding confidentiality. A total of 194 patients on the provisional register had either died, moved away from the area, were duplicate referrals, or an alternative diagnosis had been established, and were all excluded. After further clinical review, personal interview or review of existing medical records, the diagnosis could not be confirmed in a further 27 individuals. The final register therefore comprised 441 patients with multiple sclerosis who were alive and prevalent within the study area on 1 July 1993. The largest source of ascertainment was from departmental notes, which identified 368 (83%) of the prevalent patients. General practitioner referrals accounted for 225 (51%), the Multiple Sclerosis Society for 8 (2%), and nursing homes 13 (3%). Of the 255 patients notified from a single source, 199 (45%) were derived from departmental notes, 53 (12%) from general
The diagnostic classification of the 441 prevalent patients is shown in Table 1. The prevalence of multiple sclerosis in south Cambridgeshire on the 1 July 1993 was 441/290 (152/10^5; 95% confidence interval (CI) 138–167); 380 (131/10^5; 95% CI 118, 145) had either probable or definite disease and 61 (21/10^5; 95% CI 16, 27) suspected disease. Figure 1 shows the age and sex specific prevalence of multiple sclerosis in the Cambridge Health District; this ranged from 12/10^5 in the 15–24 years age group (males 4/10^5, females 2/10^5) to 410/10^5 in the 45–54 years age group (males 236/10^5, females 586/10^5). The sex ratio was 2·6 F:M. The mean age of prevalent patients was 49 (range 18–85) years; the mean age at onset was 31·7 (range 10–61) years and the mean age at diagnosis was 37·5 years. Mean disease duration was 17·3 years, from which a crude estimate of mean life expectancy of 34·6 years can be made by doubling disease duration, as first suggested by Poskanzer et al. Standardisation of prevalence to age and sex structure based on the 1961 census population of Northern Ireland demonstrated a standardised prevalence rate (SPR) of 179/10^5 (95% CI 164, 195).

Of the 374 patients registered in the original study, 303 (81%) remained prevalent, 29 (8%) had died, 29 (8%) had moved out of the study area, and 6 (1.6%) were considered not to have multiple sclerosis. All except one of these had previously been classified as having suspected disease; two had a functional illness, one had neurosarcoid, one focal cerebellar atrophy, one cerebralvascualr disease, and one a thoracic spinal meningioma. Seven patients were untraceable. Thirty six (69%) of the 52 patients originally classified as having suspected multiple sclerosis in the 1990 study remained in this diagnostic category; 11 (21%) were reclassified as having probable or definite disease either because new neurological events had occurred or on the basis of investigations and/or information relating to previously documented clinical events the significance of which had not previously been appreciated. The conversion rate of possible multiple sclerosis to probable or definite diagnostic categories was estimated at 7% per year.

Twenty nine patients had died during 1990–93. The age at death ranged from 40–85 years with a mean of 64·2 years. The mean disease duration in this cohort of patients, derived from historical or clinical records of the first neurological symptoms considered unequivocally to be due to multiple sclerosis, was 28·2 years (range 11–38) – considerably less than the figure estimated for the entire prevalent population (34·6 years). The annual mortality rate for all prevalent cases is 3·3/10^5/year.

The updated prevalence of 152/10^5 (SPR 179/10^5) represents an 18% increase over the figure obtained in 1990. Of the 138 patients newly ascertained to the study, 8 (6%) had recently moved into the study area; 58 (42%) were living in the study area in 1990 and would have had enough clinical and/or historical evidence to have been registered at that time. In 12 (9%) patients, the route of entry onto the
Multiple sclerosis in south Cambridgeshire

Discussion

The updated prevalence of multiple sclerosis in the south Cambridgeshire area was 152/10^5. Apart from a small study of 62 patients in rural Suffolk in 1988, which recorded a combined prevalence of 197/10^5 for all disease classifications, this is the highest recorded figure for England and represents an 18% increase from 1990. It is significantly higher than prevalence data for two contemporary studies which also used the Poser disease classification and included all diagnostic categories in the southern United Kingdom—south Glamorgan 1985 (117/10^5 95% CI; 107, 129)^12 and Southampt 1987 (99/10^5 95% CI; 89, 109). The survey from Sutton in 1985^14 used the Allison and Millar diagnostic criteria,^7 but reported a lower prevalence (115/10^5; 95% CI 100, 132) than in Cambridge. Three more recent epidemiological studies are difficult to interpret since these are restricted to probable and definite multiple sclerosis only. For these disease categories, the three year follow up prevalence data for south Cambridgeshire remain significantly higher than Guernsey (87/10^5; 95% CI 66, 113)^15 and Mid-Downs (111/10^5; 95% CI 103, 120),^18 and also just reach significance for the small island population of Jersey (113/10^5; 95% CI 92, 138).^17

Higher rates of disease prevalence on second surveys are a well recognised but inconsistent phenomenon. Although they may result from increased chance, the change is usually attributed to improved case ascertainment. The accurate prospective monitoring of a population with multiple sclerosis allows the relative contribution of each factor to be assessed. If the 58 previously unascertained patients had been included in the 1990 study, this would have increased the prevalence to 150/10^5 at that time. Only a small component of the new figure can therefore be attributed to an increase in incidence over the same period. We therefore believe that the most recent figure represents more accurately the true prevalence rate in south Cambridgeshire.

The effects of population migration within the study area may also partly account for the observed increase in ascertainment. Twenty nine patients prevalent in 1990 had left the area compared with eight who had moved in, representing a net emigration of 21 individuals. Population instability might be expected in an area where the major demographic centre is a university city. Temporary residents may remain registered with general practitioners outside the area, resulting in a time lag before local medical services become aware of their presence, particularly those with mild disease. Alternatively the disproportionately large cohort of young people may artificially inflate prevalence as a whole.

Prevalence is the product of incidence and disease duration and will alter with variation in either. Significant changes in incidence over time have been recorded in north east Scotland and the Orkney and Shetland Islands, and these changes have been attributed to alterations in environmental exposure. However, the recorded incidence of disease may also be influenced by improved diagnostic facilities and techniques, and by local changes in clinical practice and diagnostic categorisation. These variations in methodology have plagued direct comparison of prevalence studies conducted at different times. The relationship of incidence to prevalence in a chronic disease such as multiple sclerosis is difficult to interpret without the benefit of long term studies of incidence which monitor temporal change, especially since disease duration and hence prevalence are influenced by treatments which improve management of disease complications.

Studies of incidence and mortality are likely to be the most reliable method of predicting future epidemiological patterns of disease. These provide evidence for changes in aetiological risk factors with time and are useful in planning the distribution of health care resources. It is also important to know the true prevalence for the study area, assuming stable incidence, disease duration, and population structure. Since the mean duration of disease in our population calculated from prevalence and mortality data is 28-2 years, the estimated prevalence is 186/10^5. The 1990 study yielded 70% (130/10^5) and this has increased in the most recent survey to 82% (152/10^5). An estimated 18% therefore remain to be ascertained; clearly some individuals have only trivial manifestations of disease and are yet to present to a physician. Concerns about confidentiality and reluctance to notify patients with suspected and mild disease will also contribute to incomplete ascertainment. Patients who tend to be overlooked also include those moving in and out of areas where population dynamics are poorly documented. Our figures

![Figure 3 Serial prevalence studies of multiple sclerosis in the United Kingdom. All cases of multiple sclerosis based on Allison and Millar criteria except for SE Wales 1988 where information is available only for the Poser criteria.](http://jech.bmj.com/ first published as 10.1136/jech.50.3.274 on 1 June 1996. Downloaded from http://jech.bmj.com/ on January 8, 2021 by guest. Protected by copyright.)
demonstrate that even carefully performed studies on previously unsurveyed populations may significantly underestimate prevalence.

It is difficult to say what role these factors may have played in other geographical areas that have been subject to serial studies, but it is of interest that although the most recently reported prevalence from north east Scotland was 178/105, the statistics for 1970 and 1973 were 127/105 and 144/105, respectively. These closely relate to the three year increase seen in south Cambridgeshire and also to the estimated maximum prevalence. Analysis of serial studies within the United Kingdom demonstrates an increase in prevalence for all second, third, and fourth studies irrespective of latitude (fig 3). A fifth study of the Orkney Islands demonstrates a small fall in prevalence from 309/105 in 1974 to 240/105 in 1983, but whether this represents a true fall in incidence or reflects saturation of ascertainment from repeated surveys is unclear. However, these areas also demonstrate equivalent effects of increased case ascertainment on second surveys, although the effect is less marked in subsequent studies. In north east Scotland, 50 (8%) patients who would have been prevalent in 1970 were identified in 1973 and 18 (2%) who would have been prevalent in 1973 were identified in 1980. In the Orkney and Shetland Islands respectively, 26 (153%) and 14 (64%) patients were identified in 1974 who had a disease onset prior to the first study in 1954 and were only identified after three further studies. There were 6 (1%) patients in south east Wales in 1988 who would have been prevalent in 1985.

Table 2 shows that no equivalent data are available for Northern Ireland.

Over the years there has been considerable variation in regional incidence figures within the United Kingdom. From 12/0/105 in the Orkneys between 1940 and 1944 to 2/4/103 in Stamford, Lincolnshire in 1949. Direct methodological comparison is difficult since diagnostic classifications in earlier studies differ, although providing all categories of disease are considered it makes little difference to total numbers. It is also likely that neurological services have been better staffed in recent years (Cambridge has four neurologists compared with only one in Aberdeen at the inception of its register). Furthermore, it is not possible to produce incidence data standardised for age and sex from available population data and differences in population age and sex structures over time may make a substantial impact on comparability and the validity of conclusions reached. However, prospective incidence registers are still likely to provide the most accurate figures for the underlying frequency in a defined area.

In table 2 we have listed data for contemporary incidence figures within the United Kingdom and estimated prevalence from disease duration. Two classes of information exist: firstly, the more robust one derived from prospective registers recorded by neurologists working from a regional centre or, in the case of the Orkney and Shetlands, by the chief medical officer; and secondly, data derived from retrospective age of onset information collected in cross sectional studies, which have uniformly employed multiple ascertainment sources similar to this study. The similarities of recent estimates for incidence and prevalence irrespective of latitude and despite persistent differences in observed prevalence, suggest that there is more uniform distribution of multiple sclerosis than has hitherto been assumed.

Clearly the claim for a latitudinal gradient of disease does not rely entirely on the observations of disease frequency within the United Kingdom, but these do have particular importance since the claim for a steep gradient was responsible for generating many early hypotheses on the pathogenesis of multiple sclerosis. Latitudinal gradients have also been recorded within New Zealand, Australia, and North America, although it is relevant that earlier analyses have failed to incorporate the impact of race on geographical distribution. In Europe, evidence for a disease gradient was based primarily on serial studies from the United Kingdom and those carried out in Italy between 1959 and 1975 reporting prevalences varying between 5 and 25/105. More recent studies from Italy and other southern European countries, based on improved case ascertainment and consistent diagnostic classification, suggest that prevalence in these areas is higher than was first appreciated, and examination of incidence data alone in the 1980s within Europe has the effect of removing the direct relationship to latitude. Taken as a whole these observations bring into question the presence of a direct relationship between disease frequency and latitude within the United Kingdom, where the disease gradient has until recently been considered to be the steepest in the world.
Multiple sclerosis in south Cambridgeshire